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Summary 
Background: Despite the proven clinical effect of oral
antiplatelet drugs, a considerable number of patients do
not have an adequate response to clopidogrel. The aim of
our study was to determine the influence of CYP2C19*2
loss-of-function variant allele on clopidogrel responsiveness
in patients with carotid artery stenosis. 
Methods: One hundred and twelve patients with carotid
artery stenosis undergoing endarterectomy were included
in this one-year prospective study. All of them received
clopidogrel (75 mg daily) for at least 30 days after the
intervention. They were followed from the moment of hos-
pital admission. CYP2C19*2 genotyping was performed by
TaqMan Assay. The influence of CYP2C19*2 variant allele
on clopidogrel platelet reactivity was determined using
multiple-electrode aggregometry (MEA).
Results: Genotyping results showed that 82 (73.2%)
patients were homozygous for wild type, 29 (25.9%) were
heterozygous for the CYP2C19*2 allele and 1 (0.9%) was
CYP2C19*2 homozygous. After 24 hours, among those
with the wild type 29.3% were clopidogrel responders, and
in those with the CYP2C19*2 alleles 10%. In the wild type
group, 74.4% were clopidogrel responders after 7 days of
Kratak sadr`aj
Uvod: I pored dokazanog klini~kog efekta oralne antiagre-
gacijske terapije, zna~ajan broj pacijenata nema adekvatan
odgovor na primenjeni klopidogrel. Cilj na{e studije je bio
da se utvrdi uticaj prisutne CYP2C19*2 varijante gena na
terapijski odgovor u toku primene klopidogrela kod pacije-
nata sa stenozom karotidne arterije.
Metode: U jednogodi{nju prospektivnu studiju uklju~eno je
112 pacijenata sa stenozom karotidne arterije kod kojih je
izvr{ena endarterektomija. Posle operativnog zahvata, pa -
cijenti su primali 75 mg dnevno klopidogrela u trajanju od
najmanje mesec dana. Svi ispitanici su pra}eni od momen-
ta prijema. Za CYP2C19 genotipizaciju kori{}en je TaqMan
test. Uticaj CYP2C19*2 alela na trombocitnu reaktivnost
ispitivan je primenom multiple-electrode aggregometry (MEA).
Rezultati: Rezultati genotipizacije su pokazali da su 82
(73,2%) ispitanika homozigoti za wild-type, 29 (25,9%)
heterozigoti za CYP2C19*2 alel, dok je 1 (0,9%) bio ho mo -
 zigot za CYP2C19*2. Nakon 24 sata, u grupi sa wild-type
genotipom 29,3% ispitanika dali su odgovor na klopido-
grel, a u grupi sa CYP2C19*2 varijantom gena 10% ispi-
tanika. U grupi sa wild-type genotipom, 74,4% ispita nika
su imali terapijski odgovor nakon 7 dana, odnosno 82,9%
Abbreviations: CYP (the hepatic cytochrome P450), PCI
(per cutaneous coronary intervention), CYP2C19*2;
CYP2C19*3 (genetic polymorphism), MEA (multiple elec-
trode aggregometry), AUC (area under curve), PCR (poly-
merase chain reaction), BMI (body mass index), HDL (high
density lipoprotein), CEA (carotid endarterectomy), CCBs
(calcium channel blockers).
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Introduction
Platelets play a key role in the development of
thrombotic complications in patients with atheroscle-
rotic vascular disease (1). Oral antiplatelet drugs,
aspirin and clopidogrel are the cornerstone therapy in
conditions characterized by risk for arterial thrombosis
(1). They are widely used as treatment for patients
with acute coronary syndrome and for stent thrombo-
sis prevention in patients undergoing percutaneous
coronary intervention (2). Regarding patients under-
going carotid endarterectomy, perioperative anti -
thrombotic therapy should consist of aspirin alone,
while the addition of clopidogrel should be consid-
ered for high risk patients (3).
Despite their proven clinical effect, a consider-
able number of patients do not have an adequate
response to aspirin, clopidogrel or both (4). Ten to fif-
teen percent of patients receiving these medications
have recurrent atherothrombotic events while receiv-
ing treatment (2, 5). 
Clopidogrel is a second-generation oral thieno -
pyridine. It is a prodrug which is converted into its
active metabolite by the isoforms of hepatic cyto -
hrome P450 (CYP) in a two-step process. The active
metabolite irreversibly inhibits ADP-stimulated
platelet aggregation covalently binding to the puriner-
gic P2Y12 receptor on the platelet surface (2).
Approximately 85% is hydrolized into an inactive car-
boxylic acid derivative compound by esterase and
15% of the administered clopidogrel form the active
clopidogrel thiol metabolite. The CYP2C19 enzyme is
involved in both oxidative steps of clopidogrel metab-
olism (2, 4). Several pharmacogenomic studies de -
monstrated that CYP2C19 variant alleles affect the
pharmacokinetics and pharmacodynamics of clopido-
grel and influence the interindividual heterogenity of
the clopidogrel response (2). Variant alleles for which
reduced or loss of function have been shown com-
prise CYP2C19*2 to CYP2C19*8. The CYP2C19*2
gene variant is a G681A mutation in exon 5 which
encodes for a cryptic splice variant, while a G636A
mutation in exon 4 results in a premature stop codon
in CYP2C19*3 (6). The CYP2C19*2 is the most
frequent variant allele in the Caucasian and the
African population while CYP2C19*3 to CYP2C19*8
alleles have minor clinical impact due to their low fre-
quency (<1%) (6). Individuals who are carriers of
CYP2C19*2 and CYP2C19*3 alleles have a reduced
metabolism of clopidogrel into its active metabolite
and reduced ex vivo platelet reactivity, which leads to
an increased risk of adverse cardiovascular events (5).
The CYP2C19*17 allelic variant, a C806T mutation
in exon 5, is responsible for an increased catalytic
activity. Carriage of CYP2C19*17 allele(s) results in
an increased platelet inhibition by clopidogrel due to
an enhanced formation of the active metabolite
which could lead to an increased risk of bleeding (6).
So far, studies have examined whether clopidogrel
treatment is affected by CYP2C19 variant alleles in
patients with acute coronary syndrome (7, 8), myo -
cardial infarction (9), coronary artery disease (10, 11)
and in patients undergoing percutaneous coronary
intervention (PCI) (12–16). 
According to the published data, the presence
of CYP2C19*2 variant allele(s) leads to a reduction in
clopidogrel-induced platelet inhibition. The aim of
our study was to determine the influence of
CYP2C19*2 loss-of-function variant allele on clopido-
grel responsiveness in patients with carotid artery
stenosis undergoing endarterectomy. 
Materials and Methods
Patients 
From June 2012 to October 2013, 112 consec-
utive patients with carotid artery stenosis undergoing
elective endarterectomy (CEA) at Institute for Cardio -
vascular Diseases »Dedinje«, Belgrade, were enrolled
in the prospective study. The patients’ characteristics
are show in Table I.
Related to the study criteria, all participants who
received clopidogrel (75 mg daily) for at least 30 days
from intervention were eligible for the study.
Exclusion criteria were renal and/or liver dysfunction,
diabetes mellitus, preoperative platelet count below
150x109/L, intake of antiplatelet drugs other than
taking the drug; 82.9% after 30 days of clopidogrel intro-
duction, respectively. In patients with the CYP2C19*2 alle-
les the number of responders increased up to 46.7% after
7 days; 53.3% after 30 days of taking the drug, respective-
ly. The risk for being a low-responder is higher for the
patients heterozygous for the CYP2C19*2 allele vs. wild-
type (OR 4.250, 95% CI 1.695–10.658, P<0.01).
Conclusions: The CYP2C19*2 loss-of-function variant allele
has significant influence on clopidogrel response in patients
with carotid artery stenosis undergoing endarterectomy.
Keywords: clopidogrel, CYP2C19*2, platelet reactivity
nakon 30 dana od primene klopidogrela. U grupi sa
CYP2C19*2 alelom broj ispitanika sa terapijskim odgo -
vorom raste do 46,7% nakon 7 dana, odnosno do 53,3%
nakon 30 dana od primene klopidogrela. Rizik za slab od -
govor je ve}i kod nosilaca CYP2C19*2 alela u odnosu na
nenosioce (wild-type) (OR 4,250, 95% CI 1.695 –10.658,
P<0,01). 
Zaklju~ak: CYP2C19*2 varijanta gena zna~ajno uti~e na
terapijski odgovor u toku primene klopidogrela kod boles -
nika sa stenozom karotidne arterije kod kojih je izvr{ena
endarterektomija. 
Klju~ne re~i: klopidogrel, CYP2C19*2 varijanta gena,
reaktivnost trombocita
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aspirin and clopidogrel. On admission patients were
initially treated with aspirin. During their hospital stay
after elective CEA, in all of them a dual combination
of aspirin and clopidogrel of 75 mg was continued.
The patients were followed up for 12 months from
the moment of hospital admission. Patient compli-
ance was assessed by telephone interviews. The out-
comes that were evaluated during follow up were TIA,
stroke and death. 
The research protocol was approved by the
Ethics Committee of the Institute for Cardiovascular
Di seases »Dedinje«. All patients gave written in for -
med consent for genotype determination and platelet
function testing prior to study inclusion.
Blood sampling
For whole blood impedance aggregometry,
blood samples were collected in tubes containing
heparin as anticoagulant (BD, Swingdon, UK). Blood
samples were kept at room temperature for approxi-
mately 30 min before platelet function testing. For
genetic testing, blood samples were collected in tubes
containing sodium citrate as anticoagulant (BD,
Swingdon, UK). 
Platelet function testing
For platelet function testing multiple electrode
aggregometry (MEA) is used, which has been per-
formed using the impedance aggregometer (Multi -
plate analyzer, Roche Diagnostics, Mannheim, Ger -
many). ADP-induced platelet aggregation was used to
analyze the effect of clopidogrel. The in strument con-
tinuously measures the impedance change, which is
proportional to the amount of pla telet aggregates on
the electrode wires. The area under the aggregation
curve (AUC) was used to express the aggregation
response over the measured time (AU*min). 
Platelet aggregation was measured three times
after intervention: 24 h after the first dose (75 mg) of
clopidogrel, after 7 days and 30 days of taking the
drug. In relation to the published results (17, 18), we
performed the first measurement after 24 hours of
clopidogrel in order to determine whether a lower
clopidogrel dose (75 mg) affected platelet aggrega-
tion enough to point the difference in respect to the
CY2C19*2 carriers status.
We prospectively defined low response to clopi-
dogrel by setting a cutoff point at the upper quartile
(25%) of measurements by MEA 30 days after clopi-
dogrel introduction. The pointed cutoff value of 575
AU*min was used in the assessment of therapeutic
response at all three time points of measurements.
Genotyping
Genomic DNA was isolated from whole blood
using QIAamp DNA Blood Mini Kit (QIAGEN, Hilden,
Germany) according to the supplier’s instruction.
Genotyping for CYP2C19*2 variant allele was per-
formed by TaqMan Drug Metabolism Genotyping
Assay for SNP rs4244285 (Thermo Fisher Scientific,
Life Technologies, Carlsbad, CA, US), on a 7500 Real
Time PCR System (Applied Biosystems, Foster City,
CA, USA), according to the manufacturer’s protocol.
The results were analyzed by Applied Biosystems
7500 Real-Time PCR System Sequence Detection
Software v1.4.1.
Table I Baseline characteristics of patients.
SD (standard deviation), BMI (body mass index, kg/m2), CVD
(cardiovascular diseases), ACI (internal carotid artery), TIA
(transitory ischemic attack), ASA (acetylic salicylic acid),  ACE
(angiotensin converting enzyme).





< 30 91 (81.3)
> 30 21 (18.8)
Risk factors, n (%)
Smoking status/yes 84 (75.0)
Hypercholesterolemia/yes 40 (35.7)
Hypertriglyceridemia/yes 26 (23.2)
Positive family history of 
cardiovascular disease/yes, n (%) 41 (36.6)
Presence of stenosis of both ACI, n (%) 71 (63.4)
Previous stroke or TIA, n (%) 40 (35.7)
Stroke/yes 33 (82.5)
TIA/yes 7 (17.5)







Beta blocker 41 (36.6)
ACE inhibitor 64 (57.1)
Calcium channel blocker 35 (31.3)
Angiotensin II receptor antagonist 4 (3.6)
Statins 53 (47.3)
Statistical methodology
The normality of continuous variables was eval-
uated using the Kolmogorov-Smirnoff test. According
to the Kolmodorov-Smirnoff test, all data showed nor-
mal distribution and continuous variables are present-
ed as mean and standard deviation (SD). Categorical
variables are presented as numbers or percentages
and they were compared using Pearson chi-square
test.
Testing of the difference in ADP values at three
different moments and in two groups was performed
using two way parametric ANOVA with the Bonferroni
test for post hoc comparson. Finally, for estimating
predictors of low responsiveness, the binary logistic
regression model was used.
A P value < 0.05 was considered to indicate a
significant difference. Statistical analyses in all applied
methods were performed using SPSS version 20.0
(SPSS Inc., Chicago, Illinois).
Results
Genotyping results showed that 82 (73.2%)
patients were homozygous for wild type, 29 (25.9%)
were heterozygous for the CYP2C19*2 variant allele
and 1 (0.9%) was homozygous for CYP2C19*2. Thus,
the wild type genotype frequency was 73.2% vs.
26.8% for CYP2C19*2 carriers (Table II).
Mean and SD values of ADP-induced platelet
aggregation across CYP2C19 genotypes measured
24 h after the first dose of clopidogrel, after 7 and 30
days of taking the drug are presented in Figure 1. The
values of platelet aggregation were statistically signif-
icantly different between the two genotype groups,
P<0.01. As showed in the Figure 1, platelet aggrega-























Figure 1 ADP-induced platelet aggregation across CYP2C19 genotypes measured 24 h after the first clopidogrel dose, after 7
days and after 30 days of clopidogrel treatment.
The bottom of the box plots for ADP-induced platelet inhibition mark the 25th percentile, the median lines mark the 50th per-
centile, the top of the boxes mark the 75th percentile, the bottom and top of the vertical lines mark the 5th and 95th percentile. 
Table II Prevalence of CYP2C19 genotypes in study popula-
tion.
CYP (the hepatic cytochrome P 450)
Genotype n (%)
Wild type (CYP2C19*1/*1) 82 (73.2)
Heterozygous for CYP2C19*2 29 (25.9)
Homozygous for CYP2C19*2 1 (0.9)
tion was significantly higher in patients carrying the
CYP2C19*2 allele than in the group of non-carriers
in all three measurements; P<0.01.
Analysis of the numerical values of platelet
aggregation also showed significant difference in rela-
tion to genotype. In the group with wild type, ADP-
induced platelet aggregation showed a tendency of
decline over time. In patients with the CYP2C19*2
allele, the decline of platelet aggregation was ob -
served after 7 days of clopidogrel and remained large-
ly unchanged at the last measurement performed
after 30 days of clopidogrel intake (Table III).
The correlation between CYP2C19 genotype
and therapeutic response to clopidogrel was showed
in Table IV. The cutoff value for post-treatment mea -
surements defining the upper quartile (25%) of
patients was 575 AU*min. According to this cutoff
value, after 24 hours, in the group with the wild type
29.3% of patients were clopidogrel responders, com-
pared to only 10% from the group with the
CYP2C19*2 variant, P=0.036. In the wild type
group, 74.4% were clopidogrel responders after 7
days of taking the drug; 82.9% after 30 days of clopi-
dogrel introduction, respectively. In patients with the
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Table III ADP-induced platelet aggregation values over time across CYP2C19 genotypes.
Table IV Correlation between genotype and phenotype.
#Platelet aggregation was expressed as AU*min
ADP 24h, mean (SD)# ADP 7day, mean (SD)# P value
Wild type 672.28 (189.71) 474.63 (191.30) <0.001
Heterozygous for CYP2C19*2 763.00 (165.08) 598.80 (232.18) 0.001
ADP 7day, mean (SD)# ADP 30 day, mean (SD)# P value
Wild type 474.63 (191.30) 389.10 (183.47) <0.001
Heterozygous for CYP2C19*2 598.80 (232.18) 560.50 (257.06) 0.241
ADP 24h, mean (SD)# ADP 30 day, mean (SD)# P value
Wild type 672.28 (189.71) 389.10 (183.47) <0.001
Heterozygous for CYP2C19*2 763.00 (165.08) 560.50 (257.06) <0.001
After 24 hours of taking the drug P value
Wild type Heterozygous for CYP2C19*2 0.036
clopidogrel responder, n (%) 24 (29.3) 3 (10.0)
clopidogrel low-responder, n (%) 58 (70.7) 27 (90.0)
After 7 days of taking the drug
Wild type Heterozygous for CYP2C19*2 0.006
clopidogrel responder, n (%) 61 (74.4) 14 (46.7)
clopidogrel low-responder, n (%) 21 (25.6) 16 (53.3)
After 30 days of taking the drug
Wild type Heterozygous for CYP2C19*2 0.001
clopidogrel responder, n (%) 68 (82.9) 16 (53.3)
clopidogrel low-responder, n (%) 14 (17.1) 14 (46.7)
CYP2C19*2 alleles the number of responders in -
creased up to 46.7% after 7 days; 53.3% after 30
days of taking the drug, respectively. So, we notice a
significant difference between the two genotype
groups at the last two measurements of platelet reac-
tivity, P=0.006, P=0.001 respectively. 
The patient who was homozygous for
CYP2C19*2 had no therapeutic response from the
beginning of the treatment. The risk for being a low-
responder is higher for subjects heterozygous for the
CYP2C19*2 allele vs. wild type (OR 4.250, 95% CI
1.695–10.658). In the logistic regression model, the
CYP2C19*2 variant allele was found to be an inde-
pendent predictor of low responsiveness to clopido-
grel, P<0.01. 
In the follow up period, stroke occurred in 2
patients (1.8%). Both of them are carriers of the
CYP2C19*2 allele. Due to the size of the group who
developed stroke, we could not use any appropriate
statistical method in order to test whether there is an
influence of the CYP2C19*2 variant allele on the
development of stroke.
Discussion
To the best of our knowledge, this is the first
study in which the laboratory response to clopidogrel
was assessed to evaluate the relationship between the
CYP2C19*2 loss-of-function allele and platelet
aggregation in patients with carotid artery stenosis
undergoing CEA, who received antiplatelet treatment
with clopidogrel.
In our study group, 26.8% of patients are
CYP2C19*2 carriers, which is in line with the previous-
ly published data where 27.1% of patients were carri-
ers of at least one variant allele (6). We have to note
that our data are the first results relating to the
CYP2C19*2 variant allele frequency in a Serbian po p -
ulation. The results from our study demonstrated that
patients carrying the CYP2C19*2 allele had signifi-
cantly higher ADP-induced platelet aggregation com-
pared to the non-carriers. This is in accordance with
the results from previously published studies, which
gave evidence of a relationship between CYP2C19
variant alleles and reduced le vels of the active clopido-
grel me tabolite in the plasma (7, 10) and reduced
platelet inhibition (7, 9, 10, 12–14, 19–22) which
cause poor or absence of responsiveness to clopido-
grel and ina de quate protection from ischemic events
(7, 9, 10, 13, 14).
Analysis of the numerical values of platelet
aggregation also showed significant difference in
relation to genotype. Specifically, in the group with
wild type ADP-induced platelet aggregation showed a
tendency of decline over time, while in the group with
the CYP2C19*2 variant allele the decline in value of
platelet aggregation was observed 7 days after clopi-
dogrel treatment and remained largely unchanged. 
In our study population, one patient was homo -
zygous for CYP2C19*2 and he had no therapeutic
response from the beginning of clopidogrel treat-
ment. Our results agree with data reported by others,
where platelet aggregation values in CYP2C19*2/*2
patients are significantly higher than in CYP2C19
*1/*2 patients and the wild type genotype (13, 19). 
In our study among patients carrying the
CYP2C19*2 allele, 46.7% were clopidogrel low-
responders after 30 days of taking the drug. In con-
trast, only 27% of patients with the loss-of-function
polymorphism were classified as clopidogrel low-
responders in the Pe gasus-PCI study (16). Unlike the
Pegasus-PCI study, our study included a smaller num-
ber of patients with different clinical presentation who
were administered a lower dose of clopidogrel (75
mg). Also, a possible reason for the difference be -
tween Pegasus-PCI and our study arises from the fact
that the interval between clopidogrel intake and
blood sampling was different. Additionally, PCI leads
to the release of multiple coagulation mediators,
which additionally activate platelets (16).
Statistical analysis of our results showed that the
risk for being a clopidogrel low-responder is 4.25-fold
higher for patients heterozygous for the CYP2C19*2
allele compared to those homozygous for the wild
type. Similar results were presented in previous pub-
lished studies, too (19, 21, 23). 
We have to note that there are contrasting con-
clusions in the literature about the predictive value of
CYP2C19*2 variant allele as well as linking pharma-
codynamic response to the drug and clinical out-
comes. These uncertainties are likely due to the inac-
curacies and lack of standardization of platelet
functional tests that have been used to detect low-
responders to clopidogrel, as well as the absence of a
universally accepted and validated cutoff value for
platelet function (24). Also, it has been well docu-
mented that platelet reactivity is influenced by clinical
presentation and that choice of the best cutoff value
is disease specific. This approach would have allowed
a more accurate identification of low-responders to
clopidogrel and prediction of cardiovascular out-
comes during treatment (15, 24). 
Further, we should stress the possible effect of
co-medications on clopidogrel response. The data
concerning statin–clopidogrel interactions are incon-
sistent. In vitro studies have showed that the conver-
sion of clopidogrel into the active metabolite is inhib-
ited by atorvastatin, but in vivo studies in healthy
volunteers could not confirm an interaction between
lipophilic statins and clopidogrel, especially when
evaluations were performed with patients receiving
maintenance therapy or after they had been given a
600 mg loading dose of clopidogrel (26–28). More -
over, a recent study showed that the addition of high-
dose atorvastatin (80 mg) for 30 days significantly
improved the pharmacodynamic effects of double-
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dose clopidogrel, reducing platelet reactivity and
improving optimal clopidogrel response in statin naïve
patients with high-on treatment platelet reactivity on
standard-dose clopidogrel (28). Some calcium chan-
nel blockers (CCBs) have strong inhibitory effects on
the drug transporter p-glycoprotein (P-gp), which may
cause de creased intestinal efflux of clopidogrel (29).
Harmsze et al. evaluated the effect of co-administa-
tion of Pgp-inhibiting CCBs (verapamil, nifedipin, dil-
tiazem, barnidipine) and non-Pgp-inhibiting CCBs
(amlo di pine) on clopidogrel platelet reactivity in
patients on dual antiplatelet therapy undergoing PCI.
According to the results, only amplodipine was asso-
ciated with a high risk of clopidogrel poor response
(30). 
Among the limitations of our study that should
be discussed is the fact that this is an observational
single-center study that involved a relatively small
number of patients and as such it should be consid-
ered as a pilot study. Also, in order to obtain clear
results about the influence of CYP2C19*2 loss-of-
function genotype on clopidogrel responsiveness, we
did not include the patients with diabetes mellitus. In
addition, we assessed only the impact of one allelic
variant of the CYP2C19 isoenzyme on clopidogrel
responsiveness. 
Conclusion
The results from our study showed that the
CYP2C19*2 loss-of-function variant allele has signifi-
cant influence on clopidogrel response in patients with
carotid artery stenosis undergoing endarterectomy.
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